Acquisition of exclusive development and commercial rights to IPH2101 in the context of a swap of products
Presentation at the AASLD Annual Meeting in San Francisco, USA
IPH 4201 enters in pre-clinical validation
Vivalis and Innate Pharma sign a collaboration and commercial license agreement
Milestone payment in IPH 24 project developed in collaboration with Novo Nordisk A/S
